Vishal Bhatnagar

12PUBLICATIONS
105CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersPalliative careGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 15, 2026
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

|Oct 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

Nina Kim, E Dianne Pulte, Lori A Ehrlich

|Oct 22, 2025
Assessing tolerability of cancer therapeutics: A regulatory perspective from the FDA Oncology Center of Excellence.

Vishal Bhatnagar, Laura Lee Johnson, Mallorie H Fiero

|Oct 13, 2025
Multi-federal agency actions to integrate patient-reported outcomes into cancer research and care.

Ashley Wilder Smith, Christine Dymek, Terri S Armstrong

|Sep 05, 2025
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Michael I Barbato, Amy K Barone, Stephanie L Aungst

|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Melanie Royce, Mirat Shah, Lijun Zhang

Pageof 2

Frequent Collaborators

8 joint publications

Richard Pazdur

6 joint publications

Laleh Amiri-Kordestani

5 joint publications

William Pierce

4 joint publications

Shenghui Tang